AI Article Synopsis

  • The study investigated how chronic hepatitis B patients respond to lamivudine treatment by analyzing changes in dendritic cells (DC) and lymphocyte subsets over 48 weeks.
  • Out of 16 patients, 11 reached consistent HBV DNA negativity, while 5 showed YMDD variants; significant changes in DC surface markers were noted between the two groups at different treatment intervals.
  • In the consistent responder group, certain DC markers improved over time, while lymphocyte levels showed some changes, whereas the YMDD variant group exhibited consistently lower levels of DC markers without significant changes in lymphocyte subsets.

Article Abstract

Background: To investigate the changes of circulating dendritic cell (DC) and lymphocytes subsets in chronic hepatitis B patients treated with lamivudine.

Methods: Sixteen chronic hepatitis B patients treated with lamivudine were included and followed up for 48 weeks in this study. Before and during lamivudine treatment, DC collected from peripheral blood sample was cultured in vitro and surface markers of DC and lymphocytes subsets were detected by flow cytometry simultaneously.

Results: Of the 16 patients, 11 were consistently HBV DNA negative in serum and HBV DNA YMDD variants appeared in 5 cases. In the consistent responder group, HLA-DR level of DC decreased transiently in 12 weeks and recovered in 48 weeks (P<0.05). At 48 weeks CD80, CD40 and CD1a were improved compared with baseline level (P<0.05). In the YMDD variant group, CD83 and HLA-DR level of DC decreased at 12 weeks treatment (P<0.05) and HLA-DR was still lower compared with baseline (P<0.05). In the consistent responder group, no significant changes occurred in lymphocyte subsets number at 12 weeks treatment, but CD4 + T cell was improved and NK cell dropped at 48 weeks compared with baseline level (P<0.05). In the YMDD variant group lymphocyte subsets had no statistically significant change.

Conclusion: In the consistent responder group, the expression of surface costimulatory molecules of DC, such as CD80 and CD40,was partly recovered after the virus of hepatitis B had been inhibited efficiently, HLA-DR levels of DC decreased transiently at 12 weeks and recovered in 48 weeks and CD4+ T cell improved and NK cell dropped at 48 weeks. In the YMDD variant group, HLA-DR levels of DC were lower consistently during treatment compared with baseline level.

Download full-text PDF

Source

Publication Analysis

Top Keywords

circulating dendritic
8
dendritic cell
8
lymphocytes subsets
8
chronic hepatitis
8
hepatitis patients
8
patients treated
8
hbv dna
8
[clinical profiles
4
profiles circulating
4
cell phenotype
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!